NeoGenomics (NEO)
(Delayed Data from NSDQ)
$13.18 USD
-0.24 (-1.79%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $13.16 -0.02 (-0.15%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Brokerage Reports
0 items in cart
NeoGenomics, Inc. [NEO]
Reports for Purchase
Showing records 81 - 100 ( 132 total )
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
The Last CMS Shoe Has Dropped, Operating Leverage Ahead
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Covance?s Acquisition Throws a Wrench in NEO?s Plans, Selling Overdone
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Continued Test Menu Expansion Bolsters Confidence in Our 2015 Estimates
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Slowly, But Surely Hacking Away at Foundation Medicine
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Volume and Impending PCa-Test Drives Urology-Focused Management Addition
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
PCa Test Launch During 1H15 Set to Bolster Robust Core Business
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D